511 related articles for article (PubMed ID: 7602102)
1. Genetic immunization against herpes simplex virus. Protection is mediated by CD4+ T lymphocytes.
Manickan E; Rouse RJ; Yu Z; Wire WS; Rouse BT
J Immunol; 1995 Jul; 155(1):259-65. PubMed ID: 7602102
[TBL] [Abstract][Full Text] [Related]
2. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
Morrison LA; Knipe DM
Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
[TBL] [Abstract][Full Text] [Related]
3. Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice.
Cui FD; Asada H; Jin ML; Kishida T; Shin-Ya M; Nakaya T; Kita M; Ishii M; Iwai M; Okanoue T; Imanishi J; Mazda O
Gene Ther; 2005 Jan; 12(2):160-8. PubMed ID: 15470476
[TBL] [Abstract][Full Text] [Related]
4. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge.
Sin JI; Kim JJ; Arnold RL; Shroff KE; McCallus D; Pachuk C; McElhiney SP; Wolf MW; Pompa-de Bruin SJ; Higgins TJ; Ciccarelli RB; Weiner DB
J Immunol; 1999 Mar; 162(5):2912-21. PubMed ID: 10072541
[TBL] [Abstract][Full Text] [Related]
5. Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice.
Cui FD; Asada H; Kishida T; Itokawa Y; Nakaya T; Ueda Y; Yamagishi H; Gojo S; Kita M; Imanishi J; Mazda O
Gene Ther; 2003 Dec; 10(25):2059-66. PubMed ID: 14595378
[TBL] [Abstract][Full Text] [Related]
6. An adenovirus-herpes simplex virus glycoprotein B recombinant (Ad-HSV.gB) protects mice against a vaccinia HSV.gB and HSV challenge.
Endresz V; Berencsi K; Gönczöl E
Acta Microbiol Immunol Hung; 1995; 42(3):247-54. PubMed ID: 8548197
[TBL] [Abstract][Full Text] [Related]
7. Viral isolation and systemic immune responses after intracameral inoculation of herpes simplex virus type 1 in Igh-1-disparate congenic murine strains.
Hemady R; Tauber J; Ihley TM; Opremcak EM; Foster CS
Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2335-41. PubMed ID: 2173686
[TBL] [Abstract][Full Text] [Related]
8. Control of acute cutaneous herpes simplex virus infection: T cell-mediated viral clearance is dependent upon interferon-gamma (IFN-gamma).
Smith PM; Wolcott RM; Chervenak R; Jennings SR
Virology; 1994 Jul; 202(1):76-88. PubMed ID: 7912023
[TBL] [Abstract][Full Text] [Related]
9. LFA-3 plasmid DNA enhances Ag-specific humoral- and cellular-mediated protective immunity against herpes simplex virus-2 in vivo: involvement of CD4+ T cells in protection.
Sin JI; Kim J; Dang K; Lee D; Pachuk C; Satishchandran C; Weiner DB
Cell Immunol; 2000 Jul; 203(1):19-28. PubMed ID: 10915558
[TBL] [Abstract][Full Text] [Related]
10. Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27.
Manickan E; Yu Z; Rouse RJ; Wire WS; Rouse BT
Viral Immunol; 1995; 8(2):53-61. PubMed ID: 8825290
[TBL] [Abstract][Full Text] [Related]
11. Herpetic stromal keratitis: an immunopathologic disease mediated by CD4+ T lymphocytes.
Doymaz MZ; Rouse BT
Invest Ophthalmol Vis Sci; 1992 Jun; 33(7):2165-73. PubMed ID: 1351475
[TBL] [Abstract][Full Text] [Related]
12. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
[TBL] [Abstract][Full Text] [Related]
13. Plasmid DNA vaccines are effective in the absence of IFNgamma.
Hassett DE; Zhang J; Whitton JL
Virology; 1999 Oct; 263(1):175-83. PubMed ID: 10544092
[TBL] [Abstract][Full Text] [Related]
14. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
Weinberg A; Merigan TC
J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge.
Banks TA; Jenkins FJ; Kanangat S; Nair S; Dasgupta S; Foster CM; Rouse BT
Virology; 1994 Apr; 200(1):236-45. PubMed ID: 8128625
[TBL] [Abstract][Full Text] [Related]
16. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD.
Zarling JM; Moran PA; Burke RL; Pachl C; Berman PW; Lasky LA
J Immunol; 1986 Jun; 136(12):4669-73. PubMed ID: 2423598
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
Frye TD; Chiou HC; Hull BE; Bigley NJ
Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
[TBL] [Abstract][Full Text] [Related]
18. Coimmunization with RANTES plasmid polarized Th1 immune response against hepatitis B virus envelope via recruitment of dendritic cells.
Ma K; Xu W; Shao X; Yanyue ; Hu L; Xu H; Yuan Z; Zheng X; Xiong S
Antiviral Res; 2007 Nov; 76(2):140-9. PubMed ID: 17655942
[TBL] [Abstract][Full Text] [Related]
19. The effect of DNA priming-protein boosting on enhancing humoral immunity and protecting mice against lethal HSV infections.
Soleimanjahi H; Roostaee MH; Rasaee MJ; Mahboudi F; Kazemnejad A; Bamdad T; Zandi K
FEMS Immunol Med Microbiol; 2006 Feb; 46(1):100-6. PubMed ID: 16420602
[TBL] [Abstract][Full Text] [Related]
20. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors.
Khanam S; Khanna N; Swaminathan S
Vaccine; 2006 Oct; 24(42-43):6513-25. PubMed ID: 16860446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
